Experience of Mutaflor Suspension Use in Preterm Infants for Immunity Improvement

Odessa National Medical University62 enrolled

Overview

EcN has been registered as a medical drug under the brand name Mutaflor® SUSPENSION in Ukraine in 2010. Indications for its clinical use are acute diarrhea in infants and toddlers including those on tube feeding tube, diarrhea in children, prophylactics of pathological colonization in newborns including premature newborns, and improvement of immunity in newborns (mature and premature). The aim of this trial was to observe efficacy and safety of Mutaflor® SUSPENSION use for immunity improvement in preterm newborn infants

Study design: open-labeled, controlled, parallel group, non-interventional 3-weeks-study with followed prospective observation during 1 week and 1 year follow-up period. Patients of group I take the probiotic Mutaflor orally in the dose 1 ml once a day during first week of life and three times per week during the second and third week of life. Patients of the group II don't take specific probiotic for immunity strengthening.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Neonatal Infection

Eligibility

Sex: ALLMin age: 12 HoursMax age: 24 HoursHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * age 12-24 hours of life; * 1st degree of prematurity (functionally mature infant, gestational age 35-36 weeks); * exclusive breast feeding during study; * both parents must sign and date an informed consent for infant's participation in the study. Exclusion Criteria: * perinatal asphyxia ( Apgar score less than 8); * significant concomitant disease (congenital birth defects, perinatal encephalopathy, TORCH - infections and other infectious disease of newborn, respiratory distress syndrome ets); * clinically significant changes in blood analyze results (if needed); * use of other probiotics or prebiotics during the first 28 days of study participation.

Locations (1)

Maternity House №5

Odesa, Ukraine

Outcomes

Primary Outcomes

The Number (Rate) of Patients With Acute Respiratory Infections

ARI: Acute Rhinitis, Acute Rhinopharyngitis, Acute Bronchitis, Acute Bronchiolitis and Pneumonia

Time frame: first 28 days of life

Secondary Outcomes

The Number (Rate) of Patients With Acute Respiratory Infections

ARI: Acute Rhinitis, Acute Rhinopharyngitis, Acute Bronchitis, Acute Bronchiolitis and Pneumonia

Time frame: first 6 month of life

The Number (Rate) of Patients With Acute Respiratory Infections

ARI: Acute Rhinitis, Acute Rhinopharyngitis, Acute Bronchitis, Acute Bronchiolitis and Pneumonia

Time frame: first 12 month of life

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.